EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Fabio Volpe iD, Carmela Nappi, Emilia Zampella iD, Erica Di Donna, Simone Maurea iD, Alberto Cuocolo iD, Michele Klain iD

Current Oncology · 03.07.2024 · 31 (7) · 3870-3884

DOI: 10.3390/curroncol31070286 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 03.07.2024. Verfasst von Fabio Volpe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University of Naples "Federico II", 80138 Naples, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Differentiated thyroid cancer (DTC) patients have an outstanding overall long-term survival rate, and certain subsets of DTC patients have a very high likelihood of disease recurrence. Radioactive iodine (RAI) therapy is a cornerstone in DTC management, but cancer cells can eventually develop resistance to RAI. Radioactive iodine-refractory DTC (RAIR-DTC) is a condition defined by ATA 2015 guidelines when DTC cannot concentrate RAI ab initio or loses RAI uptake ability after the initial therapy. The RAIR condition implies that RAI cannot reveal new met-astatic foci, so RAIR-DTC metabolic imaging needs new tracers. 18F-FDG PET/CT has been widely used and has demonstrated prognostic value, but 18F-FDG DTC avidity may remain low. Fibroblast activation protein inhibitors (FA-Pi)s, prostatic-specific membrane antigen (PSMA), and somatostatin receptor (SSTR) tracers have been proposed as theragnostic agents in experimental settings and Arg-Gly-Asp (RGD) peptides in the diagnostic trial field. Multi-targeted tyrosine kinase inhibitors are relatively new drugs approved in RAIR-DTC therapy. Despite the promising targeted setting, they relate to frequent adverse-event onset. Sorafenib and trametinib have been included in re-differentiation protocols aimed at re-inducing RAI accumulation in DTC cells. Results appear promising, but not excellent.

Conclusions

RAIR-DTC remains a challenging nosological entity. There are still controversies on RAIR-DTC definition and post-RAI therapy evaluation, with post-therapy whole-body scan (PT-WBS) the only validated criterion of response. The recent introduction of multiple diagnostic and therapeutic agents obliges physicians to pursue a multidisciplinary approach aiming to correct drug introduction and timing choice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsIodine RadioisotopesHumans

Stichwörter der Autor:innen

differentiated thyroid cancerradioactive iodinerefractory DTCtheragnosticstherapy

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Advanced Biomedical Sciences, University of Naples "Federico II", 80138 Naples, Italy.

ORCID-Profile: Fabio Volpe, Emilia Zampella, Simone Maurea, Alberto Cuocolo, Michele Klain

Zitieren

APA

Volpe, F., Nappi, C., Zampella, E., Di Donna, E., Maurea, S., Cuocolo, A., & Klain, M. (2024). Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Current Oncology, 31(7), 3870-3884. https://doi.org/10.3390/curroncol31070286

Vancouver

Volpe F, Nappi C, Zampella E, Di Donna E, Maurea S, Cuocolo A, et al. Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Current Oncology. 2024;31(7):3870-3884. doi:10.3390/curroncol31070286

BibTeX
@article{Volpe2024,
  author = {Volpe, Fabio and Nappi, Carmela and Zampella, Emilia and Di Donna, Erica and Maurea, Simone and Cuocolo, Alberto and Klain, Michele},
  title = {Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer},
  journal = {Current Oncology},
  year = {2024},
  volume = {31},
  number = {7},
  pages = {3870--3884},
  doi = {10.3390/curroncol31070286}
}
Kostenlos starten →